Yesberg N E, Henderson M, Wilson K, Law S, Cross R B
Q J Exp Physiol. 1982 Jan;67(1):97-103. doi: 10.1113/expphysiol.1982.sp002629.
Saralasin, an angiotensin II analogue and receptor blocker, was infused at 7 and 15 micrograms . min-1 into dehydrated conscious Merino ewes. This caused mean arterial blood pressure, cardiac output, heart rate and renal vascular resistance to fall, and central venous pressure to rise. Renal plasma flow was unaffected but there were significant reductions in glomerular filtration rate, filtration fraction, urine flow, sodium and potassium excretion, solute clearance and solute-free water reabsorption. It is suggested that saralasin produced these effects by inhibiting endogenous angiotensin II activity, and in particular by causing a reduction in renal post-glomerular resistance. This in turn caused a fall in glomerular filtration rate and filtration fraction. While saralasin might have had effects on renal tubular function and perhaps on vasopressin secretion, the observed effects on renal function can be explained by the decrease in glomerular filtration rate and filtration fraction.
将血管紧张素 II 类似物及受体阻滞剂沙拉新以7微克·分钟⁻¹和15微克·分钟⁻¹的剂量注入脱水的清醒美利奴母羊体内。这导致平均动脉血压、心输出量、心率和肾血管阻力下降,中心静脉压升高。肾血浆流量未受影响,但肾小球滤过率、滤过分数、尿流量、钠和钾排泄、溶质清除率及无溶质水重吸收均显著降低。提示沙拉新通过抑制内源性血管紧张素 II 活性产生这些效应,尤其是通过降低肾球后阻力。这进而导致肾小球滤过率和滤过分数下降。虽然沙拉新可能对肾小管功能以及或许对血管升压素分泌有影响,但观察到的对肾功能的影响可由肾小球滤过率和滤过分数的降低来解释。